Teva Contemplates Selling $2 Billion Active Ingredients Division

Teva Pharmaceuticals considers selling its $2 billion active pharmaceutical ingredients (API) unit as part of its "Pivot to Growth" strategy.

The company is reviewing options and gauging interest, with a decision yet to be made, reported Bloomberg on Jul. 5.

Teva's API unit produces over 400 APIs across 16 plants, serving 1,000+ customers and employing around 5,000 people. Teva spokesperson neither confirms nor denies the potential sale but highlights the unit's growth potential, said Bloomberg.

The move follows CEO Richard Francis' strategy focusing on commercial portfolio, biosimilars, generics, and targeted capital allocation. Teva aims to shift focus to high-value opportunities rather than its generics business. In 2022, Teva reported $14.9 billion in revenues, with generics sales declining to $8.6 billion across its three global regions ($9 billion in 2021). Q1 2023 sales for the company reached $3.7 billion, which is flat compared to last year.

Teva Pharmaceuticals is considering selling its API unit. © Teva...
Teva Pharmaceuticals is considering selling its API unit. © Teva Pharmaceuticals

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read